|
|
Corporate Profile: Enzon
| Summary: |
Enzon, Inc.
is a biopharmaceutical company developing and commercializing
enhanced therapeutics for life-threatening diseases
through the application of its proprietary technologies,
PEG-Modification or PEG and Single-Chain Antibodies
(SCA®). |
| Address:
|
685 Route 202/206
Bridgewater, NJ 08807 |
6925 Guion Road
Indianapolis, IN 46268 |
| Phone
#'s: |
Main |
(908) 541-8600 |
not known |
| Human Resources |
not known |
not known |
| Investor Relations |
(908) 541-8600 |
not known |
| Fax
#'s: |
Main |
(908) 575-9457 |
not known |
| Human Resources |
(908) 575-0315 |
(317) 347-2852 |
| Investor Relations |
(908) 575-9457 |
not known |
| Financial
information: |
| ENZN |
| Issued United States patents: |
Issued U.S. patents: 1976-present: patent
link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
